Skip to NavigationSkip to content

Johnson & Johnson

J&J recall plant will be closed all year

The manufacturing facility at the centre of Johnson & Johnson's product recall woes is likely to stay closed until at least the end of the year.

The Fort Washington factory in Pennsylvania was shut down in April this year after serious quality control problems led to the recall of thousands of infants' and children's liquid over-the-counter (OTC) products, including big-selling brands such as Tylenol, Benadryl and Motrin.

Congress summons J&J chief executive

The Congressional committee looking into the recalls ordered by Johnson & Johnson unit McNeil Consumer Healthcare is planning to hold a second hearing on the matter.

This time, J&J chief executive William Weldon is expected to attend, according to Edolphus Towns, the chairman of the House Committee on Oversight and Government Reform.

J&J expands recall of 'musty' products

Johnson & Johnson's manufacturing troubles continues to build with yet another recall announced this week, this time for additional lots of its Benadryl and Tylenol products that had inadvertently been omitted from a previous recall.

The latest action covers five lots of Benadryl Allergy Ultratab Tablets in 100-count bottles and Extra Strength Tylenol Rapid Release Gels in 50-count bottles which were distributed by the firm's McNeil Consumer Healthcare subsidiary in the US, Puerto Rico, Bermuda and Trinidad and Tobago.

'Phantom recall' dogs J&J at congressional hearing

Johnson & Johnson subsidiary McNeil Consumer Healthcare initiated a recall of its painkiller Motrin (ibuprofen) last year without informing the US Food and Drug Administration (FDA) there was a problem with the product, it is claimed.

The allegation was made last week by Edolphus Towns, chairman of the Committee on Oversight and Government Reform, during a hearing on J&J's recall of dozens of liquid Tylenol and children's medicines last month.

Congress to probe McNeil's GMP violations

The US Food and Drug Administration may take additional regulatory action against Johnson & Johnson subsidiary McNeil Consumer Healthcare over its quality control problems, according to new information published on its website.

And adding to the pressure on the company, it emerges that the US Congress is also planning to launch its own investigation into the recall of more than 40 over-the-counter medicines for children, including liquid formulations of Tylenol (acetaminophen), the antihistamine Zyrtec (cetirizine), cough medicine Benadryl (diphenhydramine) and painkiller Motri

More quality issues dog J&J

Johnson & Johnson's manufacturing is under the spotlight at the FDA once again for quality issues affecting its products.

At the US regulator’s request, the drugmaker is recalling 43 over-the-counter medicines for infants and children made by its McNeil Consumer Healthcare division and distributed in the US and several other markets in the Americas and Middle East.

Cordis appoints Christian Spaulding

Published on: 30/03/10

Johnson & Johnson’s vascular technology company Cordis has appointed Dr Christian Spaulding worldwide VP of medical affairs.

He assumes the role, which will see him lead the company’s global clinical strategy, on 1 June and will be based in Paris.

“I’m excited to join Cordis,” said Spaulding. “As an interventional cardiologist, I’ve enjoyed working with the corporation as an investigator. I valued the company’s high quality standards for devices and ethics in clinical research.

J&J strengthens biotech business

 Johnson & Johnson is to expand its biotech capabilities with a $2.4 billion purchase of US company Scios.

The deal, still subject to regulatory and Scios Shareholder approval, will give J&J access to Scios' Natrecor, the first new agent for over a decade to treat congestive heart failure (CHF), and SCIO-469, a new type of kinase inhibitor to treat rheumatoid arthritis, in phase II trials.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches